surmount-1 tirzepatide weight loss nondiabetic Trial SURMOUNT-2: Tirzepatide confers about 15%

for Zepbound (tirzepatide) via priority review and fast track designation for chronic weight management (CWM)

When the benefit outweighs the side effect, and when it might not For most patients, the metabolic benefits of GLP-1 therapy, including improved cardiovascular risk factors, better insulin sensitivity, reduced visceral fat, and meaningful weight loss, far outweigh a temporary or modest change in libido

Most pens are designed to be held straight (at a 90-degree angle) against the skin

Each patient will start to notice the effects of their peptides several weeks after starting treatment

However, it may occur indirectly through mechanisms such as dehydration from gastrointestinal side effects, blood pressure changes, or hypoglycemia, particularly in patients taking insulin or sulfonylureas